Inhibition of primary and metastatic tumor growth in mice by cancer-associated galactosyl transferase acceptor

D. K. Podolsky, E. A. Carter, K. J. Isselbacher

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The antitumor activity of a glycopeptide purified from human malignant effusion, termed cancer-associated galactosyltransferase acceptor (CAGA), was assessed in BALB/c mice bearing primary and metastatic tumors. Initial studies with the fast-growing KA31 and slow-growing KB521 Kirsten sarcoma-transformed mouse fibroblast cell lines confirmed their tumorigenicity and metastatic potential. Inoculation of 1 X 105 KA31 cells s.c. resulted in palpable tumor formation in recipient animals witin 14 days and death within 42 days from primary tumor growth (mean survival, 26 days; total survival, 0%). Inoculation of the slower-growing KB521 resulted in tumor formation in 85% of recipients, and tumor-bearing animals succumbed within 56 days after primary inoculation (mean survival, 48 days; total survival, 15%). Administration of CAGA by i.p. injection as a single dose or series of five daily doses (each 50 μg) inhibited primary tumor growth by 35 to 68% in animals receiving KA31 cells and by 25 to 70% in animals receiving KB521 cells. CAGA increased mean survival 50% from 26 to 38 days and total survival from 0 to 27% in animals bearing KA31-derived primary tumors. In animals beating KB521-derived tumors. CAGA increased mean survival from 48 to 90 days and total survival from 15 to 50%. Similarly, CAGA was also found to significantly inhibit formation of pulmonary metastases in animals after excision of primary tumors. CAGA administration reduced death from metastatic deposits by 55 to 66% in animals initially inoculated with the KA31 cell line and by 58 to 90% in animals initially bearing primary tumors derived from the KB521 line. There was a corresponding decrease in the number of metastatic deposits per lung after administration of CAGA. Thus, CAGA appears to have potential antitumor activity against tumors with a range of growth rates and appears to inhibit both primary and metastatic tmor growth.

Original languageEnglish (US)
Pages (from-to)4026-4030
Number of pages5
JournalCancer Research
Volume43
Issue number9
StatePublished - 1983

Fingerprint

Transferases
Growth
Survival
Neoplasms
Cell Line
Lung
Glycopeptides
galactosyltransferase acceptor
Sarcoma
Fibroblasts
Neoplasm Metastasis
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inhibition of primary and metastatic tumor growth in mice by cancer-associated galactosyl transferase acceptor. / Podolsky, D. K.; Carter, E. A.; Isselbacher, K. J.

In: Cancer Research, Vol. 43, No. 9, 1983, p. 4026-4030.

Research output: Contribution to journalArticle

@article{0d594118632a4afd8cc4fed7c5232554,
title = "Inhibition of primary and metastatic tumor growth in mice by cancer-associated galactosyl transferase acceptor",
abstract = "The antitumor activity of a glycopeptide purified from human malignant effusion, termed cancer-associated galactosyltransferase acceptor (CAGA), was assessed in BALB/c mice bearing primary and metastatic tumors. Initial studies with the fast-growing KA31 and slow-growing KB521 Kirsten sarcoma-transformed mouse fibroblast cell lines confirmed their tumorigenicity and metastatic potential. Inoculation of 1 X 105 KA31 cells s.c. resulted in palpable tumor formation in recipient animals witin 14 days and death within 42 days from primary tumor growth (mean survival, 26 days; total survival, 0{\%}). Inoculation of the slower-growing KB521 resulted in tumor formation in 85{\%} of recipients, and tumor-bearing animals succumbed within 56 days after primary inoculation (mean survival, 48 days; total survival, 15{\%}). Administration of CAGA by i.p. injection as a single dose or series of five daily doses (each 50 μg) inhibited primary tumor growth by 35 to 68{\%} in animals receiving KA31 cells and by 25 to 70{\%} in animals receiving KB521 cells. CAGA increased mean survival 50{\%} from 26 to 38 days and total survival from 0 to 27{\%} in animals bearing KA31-derived primary tumors. In animals beating KB521-derived tumors. CAGA increased mean survival from 48 to 90 days and total survival from 15 to 50{\%}. Similarly, CAGA was also found to significantly inhibit formation of pulmonary metastases in animals after excision of primary tumors. CAGA administration reduced death from metastatic deposits by 55 to 66{\%} in animals initially inoculated with the KA31 cell line and by 58 to 90{\%} in animals initially bearing primary tumors derived from the KB521 line. There was a corresponding decrease in the number of metastatic deposits per lung after administration of CAGA. Thus, CAGA appears to have potential antitumor activity against tumors with a range of growth rates and appears to inhibit both primary and metastatic tmor growth.",
author = "Podolsky, {D. K.} and Carter, {E. A.} and Isselbacher, {K. J.}",
year = "1983",
language = "English (US)",
volume = "43",
pages = "4026--4030",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Inhibition of primary and metastatic tumor growth in mice by cancer-associated galactosyl transferase acceptor

AU - Podolsky, D. K.

AU - Carter, E. A.

AU - Isselbacher, K. J.

PY - 1983

Y1 - 1983

N2 - The antitumor activity of a glycopeptide purified from human malignant effusion, termed cancer-associated galactosyltransferase acceptor (CAGA), was assessed in BALB/c mice bearing primary and metastatic tumors. Initial studies with the fast-growing KA31 and slow-growing KB521 Kirsten sarcoma-transformed mouse fibroblast cell lines confirmed their tumorigenicity and metastatic potential. Inoculation of 1 X 105 KA31 cells s.c. resulted in palpable tumor formation in recipient animals witin 14 days and death within 42 days from primary tumor growth (mean survival, 26 days; total survival, 0%). Inoculation of the slower-growing KB521 resulted in tumor formation in 85% of recipients, and tumor-bearing animals succumbed within 56 days after primary inoculation (mean survival, 48 days; total survival, 15%). Administration of CAGA by i.p. injection as a single dose or series of five daily doses (each 50 μg) inhibited primary tumor growth by 35 to 68% in animals receiving KA31 cells and by 25 to 70% in animals receiving KB521 cells. CAGA increased mean survival 50% from 26 to 38 days and total survival from 0 to 27% in animals bearing KA31-derived primary tumors. In animals beating KB521-derived tumors. CAGA increased mean survival from 48 to 90 days and total survival from 15 to 50%. Similarly, CAGA was also found to significantly inhibit formation of pulmonary metastases in animals after excision of primary tumors. CAGA administration reduced death from metastatic deposits by 55 to 66% in animals initially inoculated with the KA31 cell line and by 58 to 90% in animals initially bearing primary tumors derived from the KB521 line. There was a corresponding decrease in the number of metastatic deposits per lung after administration of CAGA. Thus, CAGA appears to have potential antitumor activity against tumors with a range of growth rates and appears to inhibit both primary and metastatic tmor growth.

AB - The antitumor activity of a glycopeptide purified from human malignant effusion, termed cancer-associated galactosyltransferase acceptor (CAGA), was assessed in BALB/c mice bearing primary and metastatic tumors. Initial studies with the fast-growing KA31 and slow-growing KB521 Kirsten sarcoma-transformed mouse fibroblast cell lines confirmed their tumorigenicity and metastatic potential. Inoculation of 1 X 105 KA31 cells s.c. resulted in palpable tumor formation in recipient animals witin 14 days and death within 42 days from primary tumor growth (mean survival, 26 days; total survival, 0%). Inoculation of the slower-growing KB521 resulted in tumor formation in 85% of recipients, and tumor-bearing animals succumbed within 56 days after primary inoculation (mean survival, 48 days; total survival, 15%). Administration of CAGA by i.p. injection as a single dose or series of five daily doses (each 50 μg) inhibited primary tumor growth by 35 to 68% in animals receiving KA31 cells and by 25 to 70% in animals receiving KB521 cells. CAGA increased mean survival 50% from 26 to 38 days and total survival from 0 to 27% in animals bearing KA31-derived primary tumors. In animals beating KB521-derived tumors. CAGA increased mean survival from 48 to 90 days and total survival from 15 to 50%. Similarly, CAGA was also found to significantly inhibit formation of pulmonary metastases in animals after excision of primary tumors. CAGA administration reduced death from metastatic deposits by 55 to 66% in animals initially inoculated with the KA31 cell line and by 58 to 90% in animals initially bearing primary tumors derived from the KB521 line. There was a corresponding decrease in the number of metastatic deposits per lung after administration of CAGA. Thus, CAGA appears to have potential antitumor activity against tumors with a range of growth rates and appears to inhibit both primary and metastatic tmor growth.

UR - http://www.scopus.com/inward/record.url?scp=0020552975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020552975&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 4026

EP - 4030

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 9

ER -